Tobacco, Alcohol, and Drug Use Among Young Adults with Serious Mental Illness

Overview

Journal Community Ment Health J

Specialty Health Services

Date 2024 Mar 1

PMID 38427276

Authors

Joelle C Ferron

Mary F Brunette

Kelly A Aschbrenner

Mohamed W ElSayed

Sarah I Pratt

Affiliations

Soon will be listed here.

Abstract

To inform early intervention, this study describes correlates of substance use among young people with serious mental illness (SMI) enrolled in integrated care in community mental health settings. 227 adults ages 18-35 were assessed for clinical characteristics and substance use. Logistic regressions were used to describe relationships between substance use and participant characteristics. Over a third (38.9%) reported daily cannabis, 15.9% past month other illicit drug, 13.5% frequent/heavy alcohol and 47.4% any of these; 50.2% reported daily tobacco smoking and 23.3% current vaping. Daily cannabis and tobacco were the most common combination. Alcohol, drug, and cannabis with tobacco were associated with higher mental health symptoms but not with emergency room or hospital utilization. Cannabis and other substance use was common and associated with higher symptoms but not with greater hospital utilization, suggesting that early intervention could prevent long-term negative consequences.

References

Ahmed S, Roth R, Stanciu C, Brunette M . The Impact of THC and CBD in Schizophrenia: A Systematic Review. Front Psychiatry. 2021; 12:694394. PMC: 8343183. DOI: 10.3389/fpsyt.2021.694394. View

Baker K, Lubman D, Cosgrave E, Killackey E, Yuen H, Hides L . Impact of co-occurring substance use on 6 month outcomes for young people seeking mental health treatment. Aust N Z J Psychiatry. 2007; 41(11):896-902. DOI: 10.1080/00048670701634986. View

Achtyes E, Ben-Zeev D, Luo Z, Mayle H, Burke B, Rotondi A . Off-hours use of a smartphone intervention to extend support for individuals with schizophrenia spectrum disorders recently discharged from a psychiatric hospital. Schizophr Res. 2018; 206:200-208. DOI: 10.1016/j.schres.2018.11.026. View

Brunette M, Mueser K, Babbin S, Meyer-Kalos P, Rosenheck R, Correll C . Demographic and clinical correlates of substance use disorders in first episode psychosis. Schizophr Res. 2017; 194:4-12. DOI: 10.1016/j.schres.2017.06.039. View

Callaghan R, Veldhuizen S, Jeysingh T, Orlan C, Graham C, Kakouris G . Patterns of tobacco-related mortality among individuals diagnosed with schizophrenia, bipolar disorder, or depression. J Psychiatr Res. 2013; 48(1):102-10. DOI: 10.1016/j.jpsychires.2013.09.014. View

de Azevedo Cardoso T, Mondin T, Souza L, da Silva R, Magalhaes P, Kapczinski F . Functioning in bipolar disorder with substance abuse/dependence in a community sample of young adults. J Affect Disord. 2015; 187:179-82. DOI: 10.1016/j.jad.2015.08.046. View

Carliner H, Brown Q, Sarvet A, Hasin D . Cannabis use, attitudes, and legal status in the U.S.: A review. Prev Med. 2017; 104:13-23. PMC: 6348863. DOI: 10.1016/j.ypmed.2017.07.008. View

Cather C, Brunette M, Mueser K, Babbin S, Rosenheck R, Correll C . Impact of comprehensive treatment for first episode psychosis on substance use outcomes: A randomized controlled trial. Psychiatry Res. 2018; 268:303-311. DOI: 10.1016/j.psychres.2018.06.055. View

Le Cook B, Wayne G, Kafali E, Liu Z, Shu C, Flores M . Trends in smoking among adults with mental illness and association between mental health treatment and smoking cessation. JAMA. 2014; 311(2):172-82. PMC: 5555156. DOI: 10.1001/jama.2013.284985. View

10.

Cookey J, McGavin J, Crocker C, Matheson K, Stewart S, Tibbo P . A Retrospective Study of the Clinical Characteristics Associated with Alcohol and Cannabis use in Early Phase Psychosis. Can J Psychiatry. 2020; 65(6):426-435. PMC: 7265604. DOI: 10.1177/0706743720905201. View

11.

Correll C, Robinson D, Schooler N, Brunette M, Mueser K, Rosenheck R . Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders: baseline results from the RAISE-ETP study. JAMA Psychiatry. 2014; 71(12):1350-63. DOI: 10.1001/jamapsychiatry.2014.1314. View

12.

Crockford D, Addington D . Canadian Schizophrenia Guidelines: Schizophrenia and Other Psychotic Disorders with Coexisting Substance Use Disorders. Can J Psychiatry. 2017; 62(9):624-634. PMC: 5593250. DOI: 10.1177/0706743717720196. View

13.

DSouza D, Abi-Saab W, Madonick S, Forselius-Bielen K, Doersch A, Braley G . Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol Psychiatry. 2005; 57(6):594-608. DOI: 10.1016/j.biopsych.2004.12.006. View

14.

de Waal M, Dekker J, Goudriaan A . Prevalence of Victimization in Patients With Dual Diagnosis. J Dual Diagn. 2016; 13(2):119-123. DOI: 10.1080/15504263.2016.1274067. View

15.

Glover-Wright C, Coupe K, Campbell A, Keen C, Lawrence P, Kinner S . Health outcomes and service use patterns associated with co-located outpatient mental health care and alcohol and other drug specialist treatment: A systematic review. Drug Alcohol Rev. 2023; 42(5):1195-1219. PMC: 10946517. DOI: 10.1111/dar.13651. View

16.

Grant B, Goldstein R, Saha T, Chou S, Jung J, Zhang H . Epidemiology of DSM-5 Alcohol Use Disorder: Results From the National Epidemiologic Survey on Alcohol and Related Conditions III. JAMA Psychiatry. 2015; 72(8):757-66. PMC: 5240584. DOI: 10.1001/jamapsychiatry.2015.0584. View

17.

Hasin D, Grant B . NESARC Findings on Increased Prevalence of Marijuana Use Disorders-Consistent With Other Sources of Information. JAMA Psychiatry. 2016; 73(5):532. PMC: 5023136. DOI: 10.1001/jamapsychiatry.2015.3158. View

18.

Hindocha C, Lawn W, Freeman T, Curran H . Individual and combined effects of cannabis and tobacco on drug reward processing in non-dependent users. Psychopharmacology (Berl). 2017; 234(21):3153-3163. PMC: 5660839. DOI: 10.1007/s00213-017-4698-2. View

19.

Hjorthoj C, Ostergaard M, Benros M, Toftdahl N, Erlangsen A, Traerup Andersen J . Association between alcohol and substance use disorders and all-cause and cause-specific mortality in schizophrenia, bipolar disorder, and unipolar depression: a nationwide, prospective, register-based study. Lancet Psychiatry. 2015; 2(9):801-8. DOI: 10.1016/S2215-0366(15)00207-2. View

20.

Huo T, Guo Y, Shenkman E, Muller K . Assessing the reliability of the short form 12 (SF-12) health survey in adults with mental health conditions: a report from the wellness incentive and navigation (WIN) study. Health Qual Life Outcomes. 2018; 16(1):34. PMC: 5811954. DOI: 10.1186/s12955-018-0858-2. View